- Home
- NBIX vs EHC Comparison
NBIX vs EHC Comparison
Compare NBIX & EHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NBIX | EHC |
|---|---|---|
| Founded | 1992 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Hospital/Nursing Management |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.4B | 12.4B |
| IPO Year | 1996 | 1986 |
Fundamental Metrics
Financial Performance| Metric | NBIX | EHC |
|---|---|---|
| Price | $155.43 | $112.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 19 | 8 |
| Target Price | ★ $173.79 | $141.88 |
| AVG Volume (30 Days) | ★ 969.9K | 657.7K |
| Earning Date | 10-28-2025 | 10-29-2025 |
| Dividend Yield | N/A | ★ 0.68% |
| EPS Growth | 12.44 | ★ 27.89 |
| EPS | 4.19 | ★ 5.29 |
| Revenue | $2,682,700,000.00 | ★ $5,795,600,000.00 |
| Revenue This Year | $23.76 | $11.54 |
| Revenue Next Year | $18.01 | $8.78 |
| P/E Ratio | $37.10 | ★ $21.21 |
| Revenue Growth | ★ 19.61 | 11.13 |
| 52 Week Low | $84.23 | $87.85 |
| 52 Week High | $157.67 | $127.99 |
Technical Indicators
Market Signals| Indicator | NBIX | EHC |
|---|---|---|
| Relative Strength Index (RSI) | 64.81 | 37.76 |
| Support Level | $150.26 | $111.96 |
| Resistance Level | $154.35 | $117.50 |
| Average True Range (ATR) | 4.16 | 2.14 |
| MACD | 1.07 | 0.18 |
| Stochastic Oscillator | 93.25 | 26.60 |
Price Performance
Historical ComparisonAbout NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
About EHC Encompass Health Corporation
Encompass Health Corp provides post-acute healthcare services in the United States through a network of inpatient rehabilitation hospitals. Inpatient rehabilitation contributes the majority of the firm's revenue and provides specialized rehabilitative treatment through a network of inpatient hospitals. These hospitals are concentrated in the eastern half of the United States and Texas.